# Hub71+ Life Sciences — Cohort 20

- **Type:** intake
- **Status:** open
- **Cycle:** Cohort 20
- **City:** Abu Dhabi
- **Operator:** Hub71
- **Equity:** No programme equity
- **Cost:** No application fee
- **Duration:** Access + vertical
- **Apply:** https://www.hub71.com/program/hub71-plus-life-sciences/apply
- **Page:** https://www.dxbstart.com/programs/hub71-life-sciences

Hub71+ Life Sciences is the health / biotech / medtech vertical for Cohort 20, open as of 23 August 2026 with no verified close date. Abu Dhabi has been buying this category in public. You need more than a wellness app — regulators, hospitals, or wet work. Same Access-class substance rules. Same permanent slug for future cohorts.

## Desk take

Only if life sciences is the company. A fitness tracker with a doctor on the advisory board is Access, not this row.

## Eligibility

Hub71's specialist track for life sciences startups from pre-seed to Series A that want to build and scale from Abu Dhabi.
- Open to startups in biotechnology, MedTech and digital health, from precision medicine to biomanufacturing
- Pre-seed to Series A stage companies
- At least one founder must commit to relocating long-term and building a team in Abu Dhabi
- Application requires a pitch deck (PDF) covering problem, solution, value proposition, business model, competition, market, traction, funds raised and founding team
- Four-round selection process, including pitch sessions with Hub71 ecosystem partners

## Questions

### Do they help with DOH / DHA?

The value is the Abu Dhabi health stack and partners. Confirm on the current brief; we do not speak for Hub71.

### Is there a separate grant?

Incentives live in the Hub71 / ADGM / ADIO stack. This page is the intake, not a named cheque size.


---

Source: DXBStart — the working index of the UAE startup ecosystem. Canonical page: https://www.dxbstart.com/programs/hub71-life-sciences
More machine-readable resources: https://www.dxbstart.com/llms.txt
Startups can request a listing at https://www.dxbstart.com/submit — free, editorially reviewed.